Proof of concept shows effective digital immunoassays in clinical testing with new imaging method, suggesting potential for automation.
In digital immunoassays (DIAs), imaging detection has relied on high-magnification (≥60×), high-numerical-aperture (NA, ≥0.6) oil objectives, which impede high-throughput automated imaging and instrument miniaturization. Here, we present a simple and cost-effective method for fabricating a high-refractive-index bead array (h-RIBA) substrate through the self-assembly of barium titanate glass microspheres (BTGMs) and their embedding in a PDMS membrane. Functioning like a sticky note, the h-RIBA substrate can be easily attached to material surfaces and enables clear imaging of individual quantum dots (QDs) at the single-molecule level using a 20×/0.4 NA air objective. As a proof of concept, we successfully performed magnetic bead-based DIAs for carcinoembryonic antigen (CEA) using this substrate and objective, achieving a linear range of 0–1.5 pM and a limit of detection (LOD) of 88 fM. Measured CEA concentrations in plasma are consistent with the values provided by the hospital, validating that the h-RIBA substrate is suitable for clinical testing. The h-RIBA substrate is characterized by low cost, user-friendly operation, and broad compatibility with various fluorophores and nanoparticles. Its integration with low-NA objectives provides a practical path toward automating single-molecule fluorescence imaging, thereby accelerating the translation and commercialization of the DIA technology.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: